Article Text
Electronic pages
Low-molecular-weight heparin prophylaxis does not affect mortality in acutely ill medical patients at low risk for venous thromboembolism
Statistics from Altmetric.com
Footnotes
-
Competing interests AS has received lecturing fees, travel support and consultancy fees from Actelion, Bayer, Bristol Myer Squibb, Boehringer Ingelheim, CSL Behring, Novartis, Octapharma, Pfizer and Sanofi Aventis.